{
    "Clinical Trial ID": "NCT01156987",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Healthy Volunteers",
        "  Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.",
        "  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:",
        "  an IV line is placed by nurse,",
        "  patient is placed in the 4 T MRI scanner at CMRR,",
        "  initial scout images and manual linear shims are adjusted,",
        "  Pre-contrast SWIFT T1 weighted images and T1 map are obtained,",
        "  continuous SWIFT acquisition begins immediately before contrast injection,",
        "  contrast injection,",
        "  continuous SWIFT acquisition continues for 12 min after contrast,",
        "  late enhancement images may also be obtained.",
        "  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.",
        "INTERVENTION 2: ",
        "  Breast Cancer Patients",
        "  Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.",
        "  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:",
        "  an IV line is placed by nurse,",
        "  patient is placed in the 4 T MRI scanner at CMRR,",
        "  initial scout images and manual linear shims are adjusted,",
        "  Pre-contrast SWIFT T1 weighted images and T1 map are obtained,",
        "  continuous SWIFT acquisition begins immediately before contrast injection,",
        "  contrast injection,",
        "  continuous SWIFT acquisition continues for 12 min after contrast,",
        "  late enhancement images may also be obtained.",
        "  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compar"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women with a clinically or mammographically identified suspicious breast mass that is likely to be biopsied or surgically removed.",
        "Exclusion Criteria:",
        "  Pregnancy",
        "  Ferromagnetic implants",
        "  History of shotgun wounds and shrapnel",
        "  Obesity (>250 pounds)",
        "  Cardiac pacemaker",
        "  Incompatible implanted medical device",
        "  Severe claustrophobia",
        "  Major surgeries with potential of ferromagnetic implants",
        "  Severe asthma and allergies",
        "  i-STAT system, a handheld blood analyzer (I-STAT) creatinine test, estimated glomerular filtration rate (GFR) <30",
        "  Metallic object (greater than 2 cm in length) in the breast",
        "  Metallic ink tatoo within 20 cm of the breast (approximately 8 inches)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Lesions",
        "  Number of lesions detected",
        "  Time frame: at time of read by two radiologiests, compared to biopsy within 7 days.",
        "Results 1: ",
        "  Arm/Group Title: Healthy Volunteers",
        "  Arm/Group Description: Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.",
        "  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:",
        "  an IV line is placed by nurse,",
        "  patient is placed in the 4 T MRI scanner at CMRR,",
        "  initial scout images and manual linear shims are adjusted,",
        "  Pre-contrast SWIFT T1 weighted images and T1 map are obtained,",
        "  continuous SWIFT acquisition begins immediately before contrast injection,",
        "  contrast injection,",
        "  continuous SWIFT acquisition continues for 12 min after contrast,",
        "  late enhancement images may also be obtained.",
        "  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.",
        "  Overall Number of Participants Analyzed: 8",
        "  Measure Type: Number",
        "  Unit of Measure: lesions  0",
        "Results 2: ",
        "  Arm/Group Title: Breast Cancer Patients",
        "  Arm/Group Description: Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.",
        "  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:",
        "  an IV line is placed by nurse,",
        "  patient is placed in the 4 T MRI scanner at CMRR,",
        "  initial scout images and manual linear shims are adjusted,",
        "  Pre-contrast SWIFT T1 weighted images and T1 map are obtained,",
        "  continuous SWIFT acquisition begins immediately before contrast injection,",
        "  contrast injection,",
        "  continuous SWIFT acquisition continues for 12 min after contrast,",
        "  late enhancement images may also be obtained.",
        "  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compar",
        "  Overall Number of Participants Analyzed: 23",
        "  Measure Type: Number",
        "  Unit of Measure: lesions  12"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/8 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/23 (0.00%)"
    ]
}